AdvanCell

About

AdvanCell develops Pb-212-based targeted alpha therapies and operates an on‑demand alpha isotope generator with in‑house radiopharmaceutical manufacturing to support clinical trials and partner supply.

Mission

AdvanCell develops targeted alpha-emitting radiopharmaceutical therapies and is clinical-stage. The company is advancing proprietary Lead-212 (212Pb) alpha isotope production technology to enable 212Pb-based targeted alpha therapies. With support from a recent MRFF Frontiers Initiative award, AdvanCell plans to deliver a first-in-field clinical platform trial to accelerate translation of these therapies. The program emphasizes industry–academic partnerships and combination therapy development to improve outcomes for prostate cancer patients. AdvanCell highlights building sovereign manufacturing capabilities to speed clinical translation and broader patient access. The company positions its work as practice-changing for prostate cancer care and aims to improve lives globally. AdvanCell is a clinical-stage radiopharmaceutical company developing Targeted Alpha Therapies, including a Pb-212-based PSMA program. The company’s lead candidate, ADVC001, is in a multi-center TheraPb Ph I/II dose-escalation trial enrolling the highest dose cohort for metastatic prostate cancer. AdvanCell operates a 40,000-square-foot manufacturing facility and reports a global team of about 60 employees and world-class preclinical infrastructure. The company describes a deep and developing pipeline that includes programs beyond prostate cancer such as gastroenteropancreatic neuroendocrine tumours. Recent financing will be used to expand manufacturing capacity and accelerate clinical development across its radionuclide therapy pipeline. Management states the goal of scaling manufacturing operations and progressing therapies toward commercialization. AdvanCell develops Targeted Alpha Therapies and a world‑first alpha isotope generator to address the global shortage of clinically useful alpha isotopes. The company’s platform produces alpha‑emitting isotopes on‑demand and at scale and includes in‑house radiopharmaceutical manufacturing expertise for research, pre‑clinical and clinical use. AdvanCell says its manufacturing platform enables reliable, scalable isotope supply to support both its own programs and partner radiopharmaceutical products. Management reports the company is on schedule with pre‑clinical work and is moving into first‑in‑human trials. The team includes CEO and founder Andrew Adamovich and a board with Bill Ferris AC, Adrian Patterson, Kevin Cameron, and a new Morningside appointee, Anthony Aiudi. AdvanCell has received additional support from the NSW Health Medical Devices Fund and Australia’s Research & Development Tax Incentive.

Quick Facts